Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each
of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.